PMID: 16633462Apr 25, 2006Paper

Pharmacotherapy in the treatment of Alzheimer's disease: an update.

World Psychiatry : Official Journal of the World Psychiatric Association (WPA)
Brian E Leonard

Abstract

This review summarises the pharmacological properties of the main classes of drugs in current use for the symptomatic treatment of Alzheimer's disease. These may be divided into two major groups: those enhancing cholinergic function which has been shown to be defective in the disease, and those which either directly or indirectly reduce free radical/inflammatory processes in the brain. To date, none of the drugs available has been shown to reverse the pathological changes associated with the disease. However, a number of drugs are in development which are designed to block the neurotoxic action of amyloid beta peptide and thereby reverse the underlying pathological processes. These include the gamma secretase inhibitors and vaccines against amyloid beta peptide. The limitations of these novel approaches are discussed.

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.